Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index; 5 of the 8 sources its claims cite were checked for support.

A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy

Open access

Abstract

Congenital adrenal hyperplasia (CAH) is characterized by impaired adrenal cortisol production. Hydrocortisone (synthetic cortisol) is the drug-of-choice for cortisol replacement therapy, aiming to mimic physiological cortisol circadian rhythm. The hypothalamic-pituitary-adrenal (HPA) axis controls cortisol production through the pituitary adrenocorticotropic hormone (ACTH) and feedback mechanisms. The aim of this study was to quantify key mechanisms involved in the HPA axis activity regulation and their interaction with hydrocortisone therapy. Data from 30 healthy volunteers was leveraged: Endogenous ACTH and cortisol concentrations without any intervention as well as cortisol concentrations measured after dexamethasone suppression and single dose administration of (i) 0.5–10 mg hydrocortisone as granules, (ii) 20 mg hydrocortisone as granules and intravenous bolus. A stepwise model development workflow was used: A newly developed model for endogenous ACTH and cortisol was merged with a refined hydrocortisone pharmacokinetic model. The joint model was used to simulate ACTH and cortisol trajectories in CAH patients with varying degrees of enzyme deficiency, with or without hydrocortisone administration, and healthy individuals. Time-dependent ACTH-driven endogenous cortisol production and cortisol-mediated feedback inhibition of ACTH secretion processes were quantified and implemented in the model. Comparison of simulated ACTH and cortisol trajectories between CAH patients and healthy individuals showed the importance of administering hydrocortisone before morning ACTH secretion peak time to suppress ACTH overproduction observed in untreated CAH patients. The developed framework allowed to gain insights on the physiological mechanisms of the HPA axis regulation, its perturbations in CAH and interaction with hydrocortisone administration, paving the way towards cortisol replacement therapy optimization. Graphical Abstract

Overview

CoChat Summary

## TL;DR

The paper develops a quantitative nonlinear mixed-effects model of the HPA axis that links ACTH, cortisol production, and hydrocortisone pharmacokinetics in healthy adults. Using simulations, it shows that in severe CAH, giving immediate-release hydrocortisone before the morning ACTH peak (05:00 rather than 07:00) better suppresses ACTH overproduction.

## Key findings

  • The final joint model quantified ACTH-driven cortisol production with an estimated maximal cortisol production rate of 5440 nmol/h and EC50 = 6.63 pmol/L; a typical 70 kg healthy individual remained below 50% of maximal cortisol production, about 2200 nmol/h.
  • Cortisol feedback inhibition on ACTH secretion was modeled with an estimated IC50 = 4.60 nmol/L unbound cortisol (about 160 nmol/L total cortisol) and Imax fixed to 99.9%, implying ACTH pulsatile secretion was almost fully suppressed during daytime.
  • In simulations, mild CAH produced cortisol trajectories similar to healthy individuals, but ACTH morning peak concentrations were about 10-fold higher; severe CAH produced negligible cortisol and about 100-fold higher ACTH morning peaks than healthy individuals.
  • For severe CAH, 10 mg immediate-release hydrocortisone at 05:00 reduced ACTH overproduction more than the same dose at 07:00; dosing at 07:00 looked similar to untreated severe CAH because it was after the healthy ACTH peak time.

## Methods

  • Two cross-over phase I trials in healthy male adults were analyzed: the first trial had N = 16, the second N = 14, with one participant excluded from the second trial for insufficient ACTH suppression; the total analyzed population was n = 29.
  • The modeling workflow had three steps: refine a hydrocortisone PK model, build an endogenous ACTH-cortisol model using surge functions plus baseline secretion and cortisol feedback inhibition, then merge them into a joint model with simultaneous re-estimation.
  • Model selection used GOF plots, dOFV/AIC, visual predictive checks (n = 1000), and sampling importance resampling; simulations were run for n = 1000 virtual trajectories in 70 kg healthy and CAH individuals.

## Limitations

  • The paper states that ultradian rhythm was not modeled because it would require denser-than-hourly sampling; this limits the framework to circadian behavior.
  • It states that the endogenous ACTH-cortisol submodel was developed from only N = 13 healthy participants and that some plausible variability, such as IIV on ACTH secretion peak time, could not be estimated. The text also notes several modeling assumptions: cortisol production was assumed to depend only on ACTH, and in hydrocortisone simulations severe CAH was assumed to produce no cortisol; these are acknowledged by the authors as simplifying assumptions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s10928-024-09934-7

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Hypothalamic-pituitary-adrenal axis and cortisol related pathways (red, green and yellow areas: Mineralocorticoid, androgens and glucocorticoid pathways, respectively) and their alterations in congenital adrenal hyperplasia with red box: deficient enzyme, red crosses: species with impaired production, green plus: overproduced species. ACTH: Adrenocorticotropic hormone, CRH: Corticotropic releasing hormone, 11β-HSD 1: 11β dehydrogenase type 1, 11β-HSD 2: 11β dehydrogenase type 2
Fig. 1 Hypothalamic-pituitary-adrenal axis and cortisol related pathways (red, green and yellow areas: Mineralocorticoid, androgens and glucocorticoid pathways, respectively) and their alterations in congenital adrenal hyperplasia with red box: deficient enzyme, red crosses: species with impaired production, green plus: overproduced species. ACTH: Adrenocorticotropic hormone, CRH: Corticotropic releasing hormone, 11β-HSD 1: 11β dehydrogenase type 1, 11β-HSD 2: 11β dehydrogenase type 2CC BY · PubMed Central
Fig. 2 Schematic representation of the two clinical trial designs. Orange and cyan arrows: DEX and HC administration time points, respectively; black and gray arrows: Sampling time points (Ctot: total cortisol and ACTH (study 2, period 1)) and (Ctot+Cu: total and unbound cortisol), respectively. *ACTH measured in pre-dose samples. ACTH: Adrenocorticotropic hormone, Ctot: Total concentration, Cu: Unbound concentration, DEX: Dexamethasone, HC: Hydrocortisone
Fig. 2 Schematic representation of the two clinical trial designs. Orange and cyan arrows: DEX and HC administration time points, respectively; black and gray arrows: Sampling time points (Ctot: total cortisol and ACTH (study 2, period 1)) and (Ctot+Cu: total and unbound cortisol), respectively. *ACTH measured in pre-dose samples. ACTH: Adrenocorticotropic hormone, Ctot: Total concentration, Cu: Unbound concentration, DEX: Dexamethasone, HC: HydrocortisoneCC BY · PubMed Central
Fig. 3 Goodness of fit plots (observations versus population predictions for different hydrocortisone absorption models: Left panels for the original saturable absorption model [20], middle panels for developed ABS1 (“split-dose”) model, right panels for developed ABS2 (“estimating number of transit compartments”) model. Top panels for 20 mg oral hydrocortisone administration and bottom panels for 20 mg intravenous (i.v.) bolus hydrocortisone administration
Fig. 3 Goodness of fit plots (observations versus population predictions for different hydrocortisone absorption models: Left panels for the original saturable absorption model [20], middle panels for developed ABS1 (“split-dose”) model, right panels for developed ABS2 (“estimating number of transit compartments”) model. Top panels for 20 mg oral hydrocortisone administration and bottom panels for 20 mg intravenous (i.v.) bolus hydrocortisone administrationCC BY · PubMed Central
Fig. 4 Joint hydrocortisone (cyan part) and endogenous ACTH (red part) and cortisol (blue part) model structure. Kin, ACTH = Base*Kout, ACTH; Ktr=(Ntr + 1)/MTT. ACTH: Adrenocorticotropic hormone, ALB: Albumin, Base: ACTH baseline concentration, Bmax: Maximum binding capacity of CBG, CBG: Corticosteroid binding globulin, CL: Clearance, Cortisolb: Bound cortisol, Cortisolu: Unbound cortisol, DEX: Dexamethasone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, F: Bioavailability, γE: Hill factor for cortisol production, γI: Hill factor for ACTH suppression, Ka: Absorption rate constant, Kin, ACTH: ACTH baseline secretion rate constant, Kd: Dissociation constant cortisol-CBG, Kout, ACTH: ACTH elimination rate constant, Ktr: Transit rate constant, IC50: Unbound cortisol concentration yielding half-maximum ACTH suppression, IDEX: Dexamethasone-driven ACTH suppression, Imax: Maximum ACTH suppression by unbound cortisol, MTT: Mean transit time of oral hydrocortisone, Ntr: Number of transit compartments for oral hydrocortisone absorption, NS: Nonspecific binding cortisol-albumin, Pt1: Peak time morning surge, Pt2: Peak time midday surge, Q: Intercompartmental flow, SA1: Amplitude morning surge, SA2: Amplitude midday surge, SW1: Width morning surge, SW2: Width midday surge, Tn: nth transit compartment, Vc: Central volume of distribution, Vp: Peripheral volume of distribution
Fig. 4 Joint hydrocortisone (cyan part) and endogenous ACTH (red part) and cortisol (blue part) model structure. Kin, ACTH = Base*Kout, ACTH; Ktr=(Ntr + 1)/MTT. ACTH: Adrenocorticotropic hormone, ALB: Albumin, Base: ACTH baseline concentration, Bmax: Maximum binding capacity of CBG, CBG: Corticosteroid binding globulin, CL: Clearance, Cortisolb: Bound cortisol, Cortisolu: Unbound cortisol, DEX: Dexamethasone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, F: Bioavailability, γE: Hill factor for cortisol production, γI: Hill factor for ACTH suppression, Ka: Absorption rate constant, Kin, ACTH: ACTH baseline secretion rate constant, Kd: Dissociation constant cortisol-CBG, Kout, ACTH: ACTH elimination rate constant, Ktr: Transit rate constant, IC50: Unbound cortisol concentration yielding half-maximum ACTH suppression, IDEX: Dexamethasone-driven ACTH suppression, Imax: Maximum ACTH suppression by unbound cortisol, MTT: Mean transit time of oral hydrocortisone, Ntr: Number of transit compartments for oral hydrocortisone absorption, NS: Nonspecific binding cortisol-albumin, Pt1: Peak time morning surge, Pt2: Peak time midday surge, Q: Intercompartmental flow, SA1: Amplitude morning surge, SA2: Amplitude midday surge, SW1: Width morning surge, SW2: Width midday surge, Tn: nth transit compartment, Vc: Central volume of distribution, Vp: Peripheral volume of distributionCC BY · PubMed Central
Fig. 5 Simulations of 70 kg healthy individuals (n = 1000) (A) ACTH concentration-time profile and (B) subsequent cortisol production rate (y-axis break). (C) Total cortisol concentration-time profile and (D) subsequent suppression of ACTH pulsatile secretion. Solid lines: Typical profiles. Shaded areas: 90% confidence interval. ACTH: Adrenocorticotropic hormone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, IC50: Unbound cortisol concentration yielding half-maximum ACTH suppression
Fig. 5 Simulations of 70 kg healthy individuals (n = 1000) (A) ACTH concentration-time profile and (B) subsequent cortisol production rate (y-axis break). (C) Total cortisol concentration-time profile and (D) subsequent suppression of ACTH pulsatile secretion. Solid lines: Typical profiles. Shaded areas: 90% confidence interval. ACTH: Adrenocorticotropic hormone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, IC50: Unbound cortisol concentration yielding half-maximum ACTH suppressionCC BY · PubMed Central
Fig. 6 Simulations of 70 kg healthy individuals and CAH patients with mild and severe disease (expressed as different enzymatic activity (Emax)) (n = 1000). Top panel: Cortisol concentrations comparison between healthy state and in CAH patients. Bottom panel: Resulting ACTH concentration time profiles under those conditions; y-axis on log-scale. ACTH: Adrenocorticotropic hormone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, IC50: Total cortisol concentration yielding half-maximum ACTH suppression
Fig. 6 Simulations of 70 kg healthy individuals and CAH patients with mild and severe disease (expressed as different enzymatic activity (Emax)) (n = 1000). Top panel: Cortisol concentrations comparison between healthy state and in CAH patients. Bottom panel: Resulting ACTH concentration time profiles under those conditions; y-axis on log-scale. ACTH: Adrenocorticotropic hormone, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, IC50: Total cortisol concentration yielding half-maximum ACTH suppressionCC BY · PubMed Central
Fig. 7 Simulations of 70 kg healthy individuals and severe CAH patients (Emax=0%) (n = 1000). Top panel: Cortisol concentrations comparison between healthy state and in CAH with and without HC administration. Bottom panel: Resulting ACTH concentration time profiles under those conditions; y-axis on log-scale. ACTH: Adrenocorticotropic hormone, CAH: Congenital adrenal hyperplasia, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, HC: Hydrocortisone, IC50: Total cortisol concentration yielding half-maximum ACTH suppression
Fig. 7 Simulations of 70 kg healthy individuals and severe CAH patients (Emax=0%) (n = 1000). Top panel: Cortisol concentrations comparison between healthy state and in CAH with and without HC administration. Bottom panel: Resulting ACTH concentration time profiles under those conditions; y-axis on log-scale. ACTH: Adrenocorticotropic hormone, CAH: Congenital adrenal hyperplasia, EC50: ACTH concentration yielding half-maximum cortisol production, Emax: Maximum cortisol production rate constant, HC: Hydrocortisone, IC50: Total cortisol concentration yielding half-maximum ACTH suppressionCC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 1 Not checked · 36 Own results and interpretations

10 more claims

Create a free account to see all 41 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 51 references

Cited by

See all 4

Metadata

Authors
Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C.
Affiliations
  • Freie Universität Berlin (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • University of Potsdam (DE)
  • University of Sheffield (GB)
Corresponding author
Michelet, Robin
Venue
Journal of Pharmacokinetics and Pharmacodynamics
Published
2024-07-08
Volume
51
Issue
6
Pages
809-824
ISSN
  • 1567-567X (ISSN-L)
  • 1573-8744
OpenAlex
W4400413471
Cited by
4
References
51
Citations by year
2026: 1 · 2025: 3
FWCI
1.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion, other-oa)
  • Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
Funders
Freie Universität Berlin
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
Keywords
congenital adrenal hyperplasia, hypothalamic-pituitary-adrenal axis, cortisol, cortisol replacement therapy, ACTH secretion, dexamethasone suppression test, diurnal cortisol rhythm, enzyme deficiency
MeSH terms
Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Circadian Rhythm, Dexamethasone, Female, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Middle Aged, Models, Biological, Pituitary-Adrenal System, Hormone Replacement Therapy, Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. https://app.cochat.ai/papers/10.1007/s10928-024-09934-7
The paper
Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024). A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-024-09934-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.